Stock Movers

On this episode of Stock Movers:- Novo Nordisk (NOVOB) won approval to sell a pill version of its obesity shot Wegovy in the US, to help people lose weight or maintain previous weight loss over the long term. The company will start selling the pill in the US in early January, and it is approved based on the results of the Oasis 4 trial, which found people taking the pill lost about 13.6% of their body weight over 64 weeks.- Johnson & Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company's talc-based baby powder for causing her asbestos-linked cancer.- ServiceNow Inc. has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. Shares have fallen over 4% on the news.See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:- Novo Nordisk (NOVOB) won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly (LLY). The shares soared by as much as 11% in Copenhagen, the biggest intraday gain since August. Novo has fallen by almost half this year amid concern about the Danish drugmaker’s ability to compete in the obesity market it pioneered.- Copper hit a fresh all-time high above $12,000 a ton due to severe mine outages and trade dislocations linked to US President Donald Trump’s tariff agenda. Shares of Albemarle climbed as a result. - The US Navy announced plans to build a new class of warship, the FF(X), as part of President Donald Trump's "Golden Fleet" bid to revive US shipbuilding. That caused shares of Huntington Ingalls Industries Inc. to rise.See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:- Shares of Novo Nordisk (NVO) soared in premarket trading after the company won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly & Co. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term.- Shares of naval shipmaker Huntington Ingalls (HII) rallied ahead of the US market open after President Trump announced the Navy will build a new “Trump-class” battleship as part of the White House push to modernize a fleet that’s been hobbled by years of cost overruns and delays.- Shares of Copenhagen-listed Orsted (ORSTED DC) declined after the company said it’s considering “all options” including legal action as it weighs how to respond to a US decision to suspend leases for five offshore wind farms, according to a statement late Monday. Orsted said its farms — Revolution Wind and Sunrise Wind — had secured all the required federal and state permits, including consulting “closely and directly” with US authorities to “to evaluate and address potential impacts to national security and defense capabilities.See omnystudio.com/listener for privacy information.

On this episode of Stock Movers: - Shares of Novo Nordisk (NVO) soared in premarket trading after the company won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly & Co. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term. - Shares of naval shipmaker Huntington Ingalls (HII) rallied ahead of the US market open after President Trump announced the Navy will build a new “Trump-class” battleship as part of the White House push to modernize a fleet that’s been hobbled by years of cost overruns and delays. - Shares of Warner Bros. Discovery (WBD) edged higher in the early session as Larry Ellison is throwing his personal fortune behind Paramount Skydance Corp.’s bid for WBD, aiming to give his son’s company an advantage in a fiercely contested takeover battle with Netflix Inc.See omnystudio.com/listener for privacy information.

On This episode of Stock Movers: - Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly. - Ryanair was fined more than €255 million ($300 million) by Italy’s antitrust watchdog for allegedly using an “abusive strategy” to thwart third-party travel agencies. - Cevian Capital raises its total holding in Akzo Nobel NV to 10.15% from ~5%, according to a filing with the Dutch financial authority AFM.See omnystudio.com/listener for privacy information.